. 2021 Mar 16;36(9):1410–1420. doi: 10.1007/s00380-021-01810-5

Table 4.

Effectiveness and safety endpoints by creatinine clearance and rivaroxaban doses in the unmatched and propensity score matched cohorts

	Unmatched cohorts						Propensity score matched cohorts
	Normal renal function group (CrCl ≥ 50 mL/min)			Renal dysfunction group (CrCl < 50 mL/min)			Normal renal function group (CrCl ≥ 50 mL/min)			Renal dysfunction group (CrCl < 50 mL/min)
	10 mg/day	15 mg/day	P value^†	10 mg/day	15 mg/day	P value^†	10 mg/day	15 mg/day	P value^†		10 mg/day	15 mg/day	P value^†
	(n = 1609)	(n = 3717)	P value^†	(n = 1372)	(n = 108)	P value^†	(n = 1314)	(n = 1314)	P value^†		(n = 108)	(n = 108)	P value^†
Effectiveness endpoint
Stroke/Systemic embolism	36 (0.88)	76 (0.83)	0.795	48 (1.46)	4 (1.57)	0.909	32 (0.96)	27 (0.84)	0.595		2 (0.74)	4 (1.57)	0.387
Ischemic stroke	26 (0.64)	55 (0.60)	0.816	36 (1.10)	4 (1.57)	0.512	23 (0.69)	21 (0.65)	0.834		2 (0.74)	4 (1.57)	0.387
All-cause death	68 (1.67)	68 (0.75)	< 0.001	121 (3.69)	13 (5.09)	0.243	46 (1.38)	31 (0.96)	0.146		7 (2.60)	13 (5.09)	0.123
Safety endpoint
Major bleeding	46 (1.13)	92 (1.01)	0.506	59 (1.80)	9 (3.53)	0.046	31 (0.93)	45 (1.40)	0.082		3 (1.11)	9 (3.53)	0.067
Non-major bleeding	177 (4.34)	456 (5.00)	0.988	168 (5.12)	14 (5.48)	0.769	143 (4.28)	181 (5.62)	0.010		8 (2.97)	14 (5.48)	0.148

Figures are number of event (%/year)

CrCl creatinine clearance

^†10 mg/day vs. 15 mg/day